Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 29, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - March 29, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/29/17 - Analyst Activity Piper Jaffray Companies Reiterates Overweight on Cara Therapeutics (NASDAQ:CARA)
Analyst Ratings For Cara Therapeutics (NASDAQ:CARA) Today, Piper Jaffray Companies reiterated its Overweight rating on Cara Therapeutics (NASDAQ:CARA) with a price target of $23.00. There are 9 buy ratings on the stock. The current consensus rating on Cara Therapeutics (NASDAQ:CARA) is Buy (Score: 3.00) with a consensus target price of $26.40 per s
3/29/17 - AP Top Health News at 8:05 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 8:16 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - British new lung cancer drug wins approval in China [Philippines News Agency]
The London stock market listed company AstraZeneca Monday announced that the China Food and Drug Administration has granted marketing authorization for its lung cancer pill Tagrisso in China. Tagrisso is designed for the treatment of adult patients with certain genetic mutations, which is the first AstraZeneca medicine approved under the CFDA's...
3/29/17 - Center Point Clinical Services' Studies Show That Pharmacist-led Interventions Increase Clinical Trial Patient Medication Adherence and Compliance and Provide Robust Study Data
Center Point Clinical Services, creator of the world's first Siteless CRO platform, announced today study results presented in two separate posters at the Academy of Managed Care Pharmacy,# AMCP2017, Managed Care and Specialty Pharmacy annual meeting in Denver, Colorado. Joe Martinez, CEO of Center Point Clinical Services and the lead author of bot
3/29/17 - Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
TOKYO, Mar 29, 2017 Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme inhibitor elenbecestat in patients with early Alzheimer's disease. The Phase III clinical trial program for elenbecestat consists of two global
3/29/17 - FDA Approves Genentech's OCREVUS? (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration approved OCREVUS? as the first and only medicine for both relapsing and primary progressive forms of multiple sclerosis. The FDA s approval of OCREVUS is the beginning of a new era for the MS community and represents a significant scientific a
3/29/17 - North American Health Headlines at 8:05 p.m. EDT
Senate, White House pass on House push to revive health bill States push to protect birth control despite failed GOP bill Democratic senator asks drugmakers about opioid sales plans Trumps says he expects a health care deal soon FDA approves 1st drug for moderate& severe eczema cases
3/29/17 - North American Health Headlines at 8:16 p.m. EDT
Senate, White House pass on House push to revive health bill States push to protect birth control despite failed GOP bill Democratic senator asks drugmakers about opioid sales plans Trump says he expects a health care deal soon FDA approves 1st drug for moderate& severe eczema cases
3/29/17 - Purdue Pharma Highlights Research from Multiple Studies at AMCP Managed Care & Specialty Pharma Annual Meeting 2017
Purdue Pharma L.P. announced today the presentation of results from six clinical and non-clinical research studies at the Academy of Managed Care Pharmacy Managed Care& Specialty Pharmacy Annual Meeting 2017 in Denver, Mar. 27-30, 2017. We are pleased to present results from several studies that show our commitment to the pain community while ad
3/29/17 - Regeneron Says FDA Okays New Eczema Drug Dupixent
PARIS- Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration approved DUPIXENT or dupilumab Injection, the first and only biologic medicine approved for the treatment of adults with moderate-to-severe atopic dermatitis or AD whose disease is not adequately controlled with topical prescription therapies, or.
3/29/17 - Type 2 diabetes reversed with new drug in mouse study [The San Diego Union-Tribune]
March 28 Type 2 diabetes has been reversed in mice with a new, orally available drug, according to a study led by San Diego scientists. The study suggests a path for developing human therapies based on the drug. Scientists led by physician-researcher Nunzio Bottini countered insulin resistance by designing a drug that restored the effectiveness o
3/28/17 - 2017 France Microbiology Automated Market: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Instrumentation ReviewMolecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screenin
Complete report $6,950. DataPack $4,500. VPGMarketResearch.com' s new report is an analysis of major business opportunities emerging in the French automated microbiology market during the next five years. The report examines key trends, reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies;...
3/28/17 - AbbVie and M2Gen Announce New Collaboration for the Oncology Research Information Exchange Network (ORIEN) Avatar Research Program
NORTH CHICAGO, Ill. and TAMPA, Fla., March 28, 2017/ PRNewswire/ AbbVie, a global biopharmaceutical company, and M2Gen, a leading health informatics solutions company, announced today that AbbVie has joined the Oncology Research Information Exchange Network Avatar Research Program. ORIEN Avatar is a collaboration between the 15 leading U.S. ca
3/28/17 - AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir G/P for the Treatment of All Major Genotypes of...
By a News Reporter-Staff News Editor at China Weekly News- AbbVie, a global biopharmaceutical company, announced that priority review has been granted by the Japanese Ministry of Health, Labour and Welfare for its investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir for the treatment of all major genotypes of the chr
3/28/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mg
ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Capecitabine Tablets, 150& 500 mg, an AB-rated generic vers
3/28/17 - Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company's Board of Directors
Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Dr. Shetty is a pharmaceutical industry executive with 36 years of experience at Johnson& Johnson and its subsidiary Janssen. Most recently Dr. Shetty served as the H
3/28/17 - Adamas Announces Data Presentation on ADS-5102 at the Academy of Managed Care Pharmacy 2017 Annual Meeting
Adamas Pharmaceuticals, Inc. today announced details regarding a poster presentation highlighting data from EASE LID, its Phase 3 efficacy study of ADS-5102 extended-release capsules for the treatment of levodopa-induced dyskinesia in patients with Parkinson s disease, to be presented at the Academy of Managed Care Pharmacy s 2017 Annual Me
3/28/17 - Adamas to Present at the 16th Annual Needham Healthcare Conference
Adamas Pharmaceuticals, Inc. today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is scheduled to present at the Needham Healthcare Conference in New York on Tuesday, April 4, 2017 at 10:40 a.m. Eastern Time.. An NDA supporting ADS-5102 for the treatment of LID in patients with Parkinson s disease is und
3/28/17 - Aerie Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the 16th Annual Needham Health
3/28/17 - Akcea Therapeutics Announces Three Additions to Board of Directors
Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, Inc., today announced three additions to the company's board of directors:. Mr. Gabrieli will serve as chairman of the board of Akcea Therapeutics. Elaine Hochberg, former chief commercial officer of Forest Laboratories. Sandford D. Smith, founder and chairman of Global Biolink Partners..
3/28/17 - Albireo to Present at Upcoming Investor Conferences
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April:. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden.
3/28/17 - Alder BioPharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming 16 th Annual Needham Healthcare Conference at 5:00 p.m. ET on Tuesday, April 4, 2017 in New York, NY. Alder BioPharmaceuticals, Inc., is a clinical-stage...
3/28/17 - Alexion Names New Chief Executive [Palestine News Agency (WAFA)]
Alexion Pharmaceuticals Inc. announced Monday the appointment of a new chief executive officer, months after a leadership shake-up and investigation into drug sales practices. Ludwig N. Hantson, who most recently was president and CEO of Baxalta, a biopharmaceutical company bought last year by Shire for $32 billion, succeeds David Brennan, who was
3/28/17 - Allergan, Paratek Announce Positive Results from Two Phase 3 Trials for Moderate-to-Severe Acne Treatment [T-break Tech (Middle East)]
Allergan, a leading global pharmaceutical company and Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced that two Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415